

REMARKS

Currently claims 1-7, 9, 11, and 12 are pending.

Applicants amend the claims to remove unintentional duplication, place them in form appropriate to US practice, and to reduce the filing fee by, *inter alia*, removing multiple dependency. Applicants note that the pharmaceutically acceptable derivative language was repeated unnecessarily in the dependent claims, so correction was made to remove the unintentional duplication. Furthermore, applicants note the "and/or" language is changed to "or" to be more appropriate for US practice.

Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,



Amy H. Fix
Attorney for Applicant
Registration No. 42,616

Date: 16 Dec. 2005
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8911
Facsimile: 919-483-7988